[시장보고서]디지털 병리학 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 유형별, 용도별, 치료 영역별, 최종 용도별, 부문별 예측(2026-2033년)

디지털 병리학 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 유형별, 용도별, 치료 영역별, 최종 용도별, 부문별 예측(2026-2033년)

Digital Pathology Market Size, Share & Trends Analysis Report By Application (Academic Research, Disease Diagnosis), By Product (Software, Device), By End Use (Diagnostic Labs, Hospitals), And Segment Forecasts, 2026 - 2033

상품코드 : 1908775

리서치사 : Grand View Research

발행일 : 2025년 12월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,782,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,258,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,211,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

디지털 병리학 시장 요약

세계의 디지털 병리학 시장 규모는 2025년에 15억 3,000만 달러로 추정되며, 2033년까지 29억 7,000만 달러에 이를 것으로 예측됩니다.

또한, 2026-2033년까지 연평균 8.6%의 성장률을 보일 것으로 예측됩니다. 이는 암 발병률 증가, 워크플로우 효율성의 중요성에 대한 관심 증가, 그리고 보다 빠른 진단 도구에 대한 수요 증가에 기인합니다.

또한, 시장에서 활동하는 주요 기업들의 신제품 출시에 대한 집중, 원격 병리 진단의 보급 확대, 신약개발과 정밀의료에 대한 관심 증가를 배경으로 한 의료 분야 투자 증가가 시장 성장을 견인하고 있습니다.

디지털 병리학 산업은 암과 같은 만성 질환의 유병률 증가에 의해 주도되고 있습니다. 암의 높은 유병률로 인해 병리학자들은 환자에게 맞춤형 치료를 할 수 있는 병리 데이터를 필요로 합니다. 따라서 진단 속도 향상, 진단 정확도 향상, 치료 결과 개선을 위한 치료 권고안을 제공할 수 있는 디지털 병리학은 병리학자들이 점점 더 선호하고 있습니다. 예를 들어, 2024년 『Breast Cancer Research』지에 게재된 연구에서는 유방암 진단에서 이미지 강조, 세분화, 분류의 정확도 향상을 위해 ResNet50, Transformer, Hover-net 등의 딥러닝 모델의 적용이 주목받고 있습니다. 이러한 사례는 시장의 성장 가능성을 보여줍니다.

의료 IT 솔루션의 도입 확대가 디지털 병리 솔루션에 대한 수요를 촉진하고 있습니다. 조직은 비용 절감, 프로세스 효율화, 자원 부족 해소, 효율적인 정보 공유를 촉진하기 위해 이러한 솔루션의 도입을 가속화하고 있습니다. 또한, 다양한 과학 분야에서의 공동연구의 필요성 증가와 디지털 문서화의 보급 확대도 수요를 견인하고 있습니다. 또한, 검사실 효율성 향상을 위한 도입 확대, 원격진료의 급증, 동반진단 및 신약개발 분야에서의 응용 확대 등의 요인도 시장 성장에 기여할 것으로 예측됩니다.

또한, 디지털 이미지의 분석 정확도 향상에 AI 기술이 활용되고 있습니다. 기존에는 병리과 의사가 조직 샘플에서 관심 영역을 수동으로 식별해야 했지만, 현재는 AI가 이 과정을 자동화하고 있습니다. 이러한 변화는 수작업에 대한 의존도를 낮추고, 인적 오류의 위험을 최소화하며, 병리 업무의 자동화를 촉진하고 있습니다.

세계의 디지털 병리학 시장 : 최종 용도별 대시보드
세계의 디지털 병리학 시장 : 최종 용도별 변동 분석
세계의 디지털 병리학 시장 추산 및 예측 : 최종 용도별, 매출별
병원
바이오테크놀러지 및 제약 기업
진단실험실
학술기관 및 연구기관

제9장 디지털 병리학 시장 : 지역별 추정 및 동향 분석

지역별 대시보드
시장 규모와 예측, 동향 분석(2021-2033년)
북미
- 미국
- 캐나다
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 러시아
- 네덜란드
- 스위스
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 태국
- 호주
- 싱가포르
- 필리핀
- 말레이시아
- 인도네시아
라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
- 튀르키예
- 이란
- 이스라엘

제10장 경쟁 구도

참가 기업 개요
디지털 병리 솔루션 제공 기업 전체 시장 현황 분석
AI탑재 디지털 병리 솔루션 제공 기업 시장 현황 분석
벤더 구도
- 유통업체 리스트
2025년 기업 점유율 분석
기업 분류
전략 매핑
디지털 병리학 솔루션 종합 프로바이더 기업 개요
- Leica Biosystems Nussloch GmbH(Danaher)
- Hamamatsu Photonics, Inc.
- Koninklijke Philips N.V.
- Olympus Corporation
- F. Hoffmann-La Roche Ltd.
- Mikroscan Technologies, Inc.
- Epredia(3DHISTECH Ltd.)
- Visiopharm A/S
- Huron Technologies International Inc.
- ContextVision AB
- CellaVision
- HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD.(MORPHOGO)
- West Medica Produktions-und Handels-GmbH(West Medica)
- aetherAI
- IBEX(IBEX MEDICAL ANALYTICS)
- SigTuple Technologies Private Limited Morphle Labs, Inc
- Morphle Labs, Inc
- Bionovation Biotech, Inc.
- Scopio labs
- Inspirata, Inc
- Path Hub
- Sectra AB
- Agfa-Gevaert Group
- OptraScan
- Agilent Technologies, Inc.
- KFBIO
AI탑재 디지털 병리 솔루션 제공 기업 개요
- Aiosyn
- Proscia Inc.
- EVIDENT
- Aignostics, Inc.
- Aiforia/Aiforia Technologies PLC
- Qritive
- Mindpeak GmbH
- Dedalus S.p.A
- Gestalt
- CGI Inc. Overview

LSH

영문 목차

영문목차

Digital Pathology Market Summary

The global digital pathology market size was estimated at USD 1.53 billion in 2025 and is projected to reach USD 2.97 billion by 2033, growing at a CAGR of 8.6% from 2026 to 2033. This is attributed to rising prevalence of cancer, increasing focus on improving the efficiency of workflow, and growing demand for faster diagnostic tools.

Moreover, rising investments in healthcare aided by major key players operating in the market focusing on new launches, increasing adoption of telepathology, and an increasing focus on drug discovery and precision medicine is propelling the market growth.

The digital pathology industry is predominantly driven by the growing prevalence of chronic diseases such as cancer. As a consequence of the high prevalence of cancer, pathologists require pathology data that can facilitate customizing of therapies for patients. Therefore, digital pathology is increasingly preferred by pathologists, as it accelerates the diagnosis rate, enhances diagnostic accuracy, and provides therapeutic recommendations to improve patient outcomes. For instance, a 2024 study published in Breast Cancer Research highlights the application of deep learning models such as ResNet50, Transformer, and Hover-net in enhancing image enhancement, segmentation, and classification for breast cancer diagnosis. Such instances signify the growth potential of the market.

Rising adoption of healthcare IT solutions is fueling the demand for digital pathology solutions. Organizations are increasingly implementing them to cut costs, streamline processes, overcome resource bottlenecks, and facilitate efficient content sharing. A growing necessity for collaborations and the expanding use of digital documentation across various scientific disciplines also drives the demand. In addition, factors such as heightened adoption to enhance laboratory efficiency, a surge in teleconsultations, and increased applications in companion diagnostics and drug discovery are expected to contribute to the market's growth.

Additionally, AI is being leveraged to enhance the analysis of digital images. Previously, pathologists had to identify regions of interest within tissue samples manually, but AI is now automating this process. This shift reduces the reliance on manual labor, minimizing the risk of human error and promoting greater automation in pathology practices.

Global Digital Pathology Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global digital pathology market based on product, application, therapeutic area, end use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Software
Device
- Scanners
- Slide Management Systems
Storage System
Type Outlook (Revenue, USD Million, 2021 - 2033)
Human Pathology
Veterinary Pathology
Application Outlook (Revenue, USD Million, 2021 - 2033)
Drug Discovery & Development
Academic Research
Disease Diagnosis
- Cancer Cell Detection
- Others
Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Cardiovascular
Neurology
Others (Including dermatology, infectious diseases, gastrointestinal, etc.)
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals
Biotech & Pharma Companies
Diagnostic Labs
Academic & Research Institutes
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Italy
- Russia
- Spain
- Netherlands
- Switzerland
- Sweden
- Denmark
- Norway
Asia Pacific
- Japan
- China
- India
- Indonesia
- Thailand
- Australia
- South Korea
- Philippines
- Malaysia
- Singapore
Latin America
- Brazil
- Argentina
- Mexico
Middle East & Africa
- South Africa
- Saudi Arabia
- Turkey
- Iran
- United Arab Emirates
- Israel
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Type
- 1.2.3. Application
- 1.2.4. Therapeutic Area
- 1.2.5. End Use
1.3. Regional scope
1.4. Estimates and forecasts timeline
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased database
- 1.6.2. GVR's internal database
- 1.6.3. Secondary sources
- 1.6.4. Primary research
- 1.6.5. Details of primary research
1.7. Information or Data Analysis
- 1.7.1. Data analysis models
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity flow analysis
1.10. List of Secondary Sources
1.11. List of Primary Sources
1.12. Objectives

Chapter 2. Executive Summary

2.1. Digital Pathology Market Snapshot
2.2. Digital Pathology Market Segment Snapshot
2.3. Digital Pathology Market Competitive Landscape Snapshot

Chapter 3. Digital Pathology Market: Component Estimates & Trend Analysis

3.1. Market Dynamics
- 3.1.1. Market driver analysis
  - 3.1.1.1. Increasing prevalence of chronic diseases
  - 3.1.1.2. Higher cost-efficiency
  - 3.1.1.3. Rapid technological advancements
  - 3.1.1.4. Increasing demand for integrated healthcare systems and patient-centric care
  - 3.1.1.5. Growing adoption of digital pathology solutions in veterinary care practices
  - 3.1.1.6. Rapid technological advancements in digital pathology solutions in veterinary field
- 3.1.2. Market restraint analysis
  - 3.1.2.1. Lack of skilled professionals
  - 3.1.2.2. High cost of implementing digital pathology solutions
- 3.1.3. Market opportunity analysis
- 3.1.4. Market challenges analysis
- 3.1.5. Industry Analysis - Porter's Five Forces Analysis
  - 3.1.5.1. Supplier power
  - 3.1.5.2. Buyer power
  - 3.1.5.3. Substitution threat
  - 3.1.5.4. Threat of new entrant
  - 3.1.5.5. Competitive rivalry
- 3.1.6. PESTEL Analysis
3.2. Technology Trend Analysis
3.3. Regulatory Framework
3.4. Cost Structure Analysis
- 3.4.1. Cost of implementation
- 3.4.2. Price erosion analysis
3.5. User Perspective Analysis
- 3.5.1. Consumer behavior analysis
3.6. Market Entry Strategies
- 3.6.1. Competitive strategies
3.7. Case Study Insights

Chapter 4. Digital Pathology Market: Product Estimates & Trend Analysis

4.1. Global Digital Pathology Market: Product Dashboard
4.2. Global Digital Pathology Market: Product Movement Analysis
4.3. Global Digital Pathology Market Estimates and Forecasts, By Product, Revenue (USD Million)
4.4. Software
- 4.4.1. Software market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Device
- 4.5.1. Devices market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5.2. Scanners
  - 4.5.2.1. Scanners market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5.3. Slide Management System
  - 4.5.3.1. Slide management system market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Storage System
- 4.6.1. Storage system market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Digital Pathology Market: Type Estimates & Trend Analysis

5.1. Global Digital Pathology Market: Type Dashboard
5.2. Global Digital Pathology Market: Type Movement Analysis
5.3. Global Digital Pathology Market Estimates and Forecasts, By Type, Revenue (USD Million)
5.4. Human Pathology
- 5.4.1. Human pathology market estimates and forecasts, 2021 to 2033 (USD Million)
5.5. Veterinary Pathology
- 5.5.1. Veterinary pathology market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Digital Pathology Market: Application Estimates & Trend Analysis

6.1. Global Digital Pathology Market: Application Dashboard
6.2. Global Digital Pathology Market: Application Movement Analysis
6.3. Global Digital Pathology Market Estimates and Forecasts, By Application, Revenue (USD Million)
6.4. Drug Discovery & Development
- 6.4.1. Drug discovery & development market estimates and forecasts, 2021 to 2033 (USD Million)
6.5. Academic Research
- 6.5.1. Academic research market estimates and forecasts, 2021 to 2033 (USD Million)
6.6. Disease Diagnosis
- 6.6.1. Disease diagnosis market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.6.2. Cancer Cell Detection
  - 6.6.2.1. Cancer cell detection market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.6.3. Others
  - 6.6.3.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Digital Pathology Market: Therapeutic Area Estimates & Trend Analysis

7.1. Global Digital Pathology Market: Therapeutic Area Dashboard
7.2. Global Digital Pathology Market: Therapeutic Area Movement Analysis
7.3. Global Digital Pathology Market Estimates and Forecasts, By Therapeutic Area, Revenue (USD Million)
7.4. Oncology
- 7.4.1. Oncology market estimates and forecasts, 2021 to 2033 (USD Million)
7.5. Cardiovascular
- 7.5.1. Cardiovascular market estimates and forecasts, 2021 to 2033 (USD Million)
7.6. Neurology
- 7.6.1. Neurology market estimates and forecasts, 2021 to 2033 (USD Million)
7.7. Others
- 7.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Digital Pathology Market: End Use Estimates & Trend Analysis

8.1. Global Digital Pathology Market: End Use Dashboard
8.2. Global Digital Pathology Market: End Use Movement Analysis
8.3. Global Digital Pathology Market Estimates and Forecasts, By End Use, Revenue (USD Million)
8.4. Hospitals
- 8.4.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
8.5. Biotech & Pharma Companies
- 8.5.1. Biotech & pharma companies market estimates and forecasts, 2021 to 2033 (USD Million)
8.6. Diagnostic Labs
- 8.6.1. Diagnostic labs market estimates and forecasts, 2021 to 2033 (USD Million)
8.7. Academic & research institutes
- 8.7.1. Academic & Research Institutes market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Digital Pathology Market: Regional Estimates & Trend Analysis by Product and End Use

9.1. Regional Dashboard
9.2. Market Size & Forecasts Trend Analysis, 2021 to 2033
9.3. North America
- 9.3.1. U.S.
  - 9.3.1.1. Key country dynamics
  - 9.3.1.2. Regulatory framework
  - 9.3.1.3. Competitive scenario
  - 9.3.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.3.2. Canada
  - 9.3.2.1. Key country dynamics
  - 9.3.2.2. Regulatory framework
  - 9.3.2.3. Competitive scenario
  - 9.3.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
9.4. Europe
- 9.4.1. UK
  - 9.4.1.1. Key country dynamics
  - 9.4.1.2. Regulatory framework
  - 9.4.1.3. Competitive scenario
  - 9.4.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.2. Germany
  - 9.4.2.1. Key country dynamics
  - 9.4.2.2. Regulatory framework
  - 9.4.2.3. Competitive scenario
  - 9.4.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.3. France
  - 9.4.3.1. Key country dynamics
  - 9.4.3.2. Regulatory framework
  - 9.4.3.3. Competitive scenario
  - 9.4.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.4. Italy
  - 9.4.4.1. Key country dynamics
  - 9.4.4.2. Regulatory framework
  - 9.4.4.3. Competitive scenario
  - 9.4.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.5. Spain
  - 9.4.5.1. Key country dynamics
  - 9.4.5.2. Regulatory framework
  - 9.4.5.3. Competitive scenario
  - 9.4.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.6. Denmark
  - 9.4.6.1. Key country dynamics
  - 9.4.6.2. Regulatory framework
  - 9.4.6.3. Competitive scenario
  - 9.4.6.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.7. Sweden
  - 9.4.7.1. Key country dynamics
  - 9.4.7.2. Regulatory framework
  - 9.4.7.3. Competitive scenario
  - 9.4.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.8. Norway
  - 9.4.8.1. Key country dynamics
  - 9.4.8.2. Regulatory framework
  - 9.4.8.3. Competitive scenario
  - 9.4.8.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.9. Russia
  - 9.4.9.1. Key country dynamics
  - 9.4.9.2. Regulatory framework
  - 9.4.9.3. Competitive scenario
  - 9.4.9.4. Russia market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.10. Netherlands
  - 9.4.10.1. Key country dynamics
  - 9.4.10.2. Regulatory framework
  - 9.4.10.3. Competitive scenario
  - 9.4.10.4. Netherlands market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.4.11. Switzerland
  - 9.4.11.1. Key country dynamics
  - 9.4.11.2. Regulatory framework
  - 9.4.11.3. Competitive scenario
  - 9.4.11.4. Switzerland market estimates and forecasts, 2021 to 2033 (USD Million)
9.5. Asia Pacific
- 9.5.1. Japan
  - 9.5.1.1. Key country dynamics
  - 9.5.1.2. Regulatory framework
  - 9.5.1.3. Competitive scenario
  - 9.5.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.2. China
  - 9.5.2.1. Key country dynamics
  - 9.5.2.2. Regulatory framework
  - 9.5.2.3. Competitive scenario
  - 9.5.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.3. India
  - 9.5.3.1. Key country dynamics
  - 9.5.3.2. Regulatory framework
  - 9.5.3.3. Competitive scenario
  - 9.5.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.4. South Korea
  - 9.5.4.1. Key country dynamics
  - 9.5.4.2. Regulatory framework
  - 9.5.4.3. Competitive scenario
  - 9.5.4.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.5. Thailand
  - 9.5.5.1. Key country dynamics
  - 9.5.5.2. Regulatory framework
  - 9.5.5.3. Competitive scenario
  - 9.5.5.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.6. Australia
  - 9.5.6.1. Key country dynamics
  - 9.5.6.2. Regulatory framework
  - 9.5.6.3. Competitive scenario
  - 9.5.6.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.7. Singapore
  - 9.5.7.1. Key country dynamics
  - 9.5.7.2. Regulatory framework
  - 9.5.7.3. Competitive scenario
  - 9.5.7.4. Singapore market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.8. Philippines
  - 9.5.8.1. Key country dynamics
  - 9.5.8.2. Regulatory framework
  - 9.5.8.3. Competitive scenario
  - 9.5.8.4. Philippines market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.9. Malaysia
  - 9.5.9.1. Key country dynamics
  - 9.5.9.2. Regulatory framework
  - 9.5.9.3. Competitive scenario
  - 9.5.9.4. Malaysia market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.5.10. Indonesia
  - 9.5.10.1. Key country dynamics
  - 9.5.10.2. Regulatory framework
  - 9.5.10.3. Competitive scenario
  - 9.5.10.4. Indonesia market estimates and forecasts, 2021 to 2033 (USD Million)
9.6. Latin America
- 9.6.1. Brazil
  - 9.6.1.1. Key country dynamics
  - 9.6.1.2. Regulatory framework
  - 9.6.1.3. Competitive scenario
  - 9.6.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.6.2. Argentina
  - 9.6.2.1. Key country dynamics
  - 9.6.2.2. Regulatory framework
  - 9.6.2.3. Competitive scenario
  - 9.6.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.6.3. Mexico
  - 9.6.3.1. Key country dynamics
  - 9.6.3.2. Regulatory framework
  - 9.6.3.3. Competitive scenario
  - 9.6.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
9.7. MEA
- 9.7.1. South Africa
  - 9.7.1.1. Key country dynamics
  - 9.7.1.2. Regulatory framework
  - 9.7.1.3. Competitive scenario
  - 9.7.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.7.2. Saudi Arabia
  - 9.7.2.1. Key country dynamics
  - 9.7.2.2. Regulatory framework
  - 9.7.2.3. Competitive scenario
  - 9.7.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.7.3. UAE
  - 9.7.3.1. Key country dynamics
  - 9.7.3.2. Regulatory framework
  - 9.7.3.3. Competitive scenario
  - 9.7.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.7.4. Kuwait
  - 9.7.4.1. Key country dynamics
  - 9.7.4.2. Regulatory framework
  - 9.7.4.3. Competitive scenario
  - 9.7.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.7.5. Turkey
  - 9.7.5.1. Key country dynamics
  - 9.7.5.2. Regulatory framework
  - 9.7.5.3. Competitive scenario
  - 9.7.5.4. Turkey market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.7.6. Iran
  - 9.7.6.1. Key country dynamics
  - 9.7.6.2. Regulatory framework
  - 9.7.6.3. Competitive scenario
  - 9.7.6.4. Iran market estimates and forecasts, 2021 to 2033 (USD Million)
- 9.7.7. Israel
  - 9.7.7.1. Key country dynamics
  - 9.7.7.2. Regulatory framework
  - 9.7.7.3. Competitive scenario
  - 9.7.7.4. Israel market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

10.1. Participant Overview
10.2. Company Market Position Analysis of Overall Digital Pathology Solution Providers
10.3. Company Market Position Analysis of AI-enabled Digital Pathology Solution Providers
10.4. Vendor Landscape
- 10.4.1. List of Distributors
10.5. Company Market Share Analysis, 2025
10.6. Company Categorization
10.7. Strategy Mapping
10.8. Company Profiles of Overall Digital Pathology Solution Providers
- 10.8.1. Leica Biosystems Nussloch GmbH (Danaher)
  - 10.8.1.1. Overview
  - 10.8.1.2. Financial performance
  - 10.8.1.3. Product benchmarking
  - 10.8.1.4. Strategic initiatives
- 10.8.2. Hamamatsu Photonics, Inc.
  - 10.8.2.1. Overview
  - 10.8.2.2. Financial performance
  - 10.8.2.3. Product benchmarking
  - 10.8.2.4. Strategic initiatives
- 10.8.3. Koninklijke Philips N.V.
  - 10.8.3.1. Overview
  - 10.8.3.2. Financial performance
  - 10.8.3.3. Product benchmarking
  - 10.8.3.4. Strategic initiatives
- 10.8.4. Olympus Corporation
  - 10.8.4.1. Overview
  - 10.8.4.2. Financial performance
  - 10.8.4.3. Product benchmarking
  - 10.8.4.4. Strategic initiatives
- 10.8.5. F. Hoffmann-La Roche Ltd.
  - 10.8.5.1. Overview
  - 10.8.5.2. Financial performance
  - 10.8.5.3. Product benchmarking
  - 10.8.5.4. Strategic initiatives
- 10.8.6. Mikroscan Technologies, Inc.
  - 10.8.6.1. Overview
  - 10.8.6.2. Financial performance
  - 10.8.6.3. Product benchmarking
  - 10.8.6.4. Strategic initiatives
- 10.8.7. Epredia (3DHISTECH Ltd.)
  - 10.8.7.1. Overview
  - 10.8.7.2. Financial performance
  - 10.8.7.3. Product benchmarking
  - 10.8.7.4. Strategic initiatives
- 10.8.8. Visiopharm A/S
  - 10.8.8.1. Overview
  - 10.8.8.2. Financial performance
  - 10.8.8.3. Product benchmarking
  - 10.8.8.4. Strategic initiatives
- 10.8.9. Huron Technologies International Inc.
  - 10.8.9.1. Overview
  - 10.8.9.2. Financial performance
  - 10.8.9.3. Product benchmarking
  - 10.8.9.4. Strategic initiatives
- 10.8.10. ContextVision AB
  - 10.8.10.1. Overview
  - 10.8.10.2. Financial performance
  - 10.8.10.3. Product benchmarking
  - 10.8.10.4. Strategic initiatives
- 10.8.11. CellaVision
  - 10.8.11.1. Overview
  - 10.8.11.2. Financial performance
  - 10.8.11.3. Product benchmarking
  - 10.8.11.4. Strategic initiatives
- 10.8.12. HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO)
  - 10.8.12.1. Overview
  - 10.8.12.2. Financial performance
  - 10.8.12.3. Product benchmarking
  - 10.8.12.4. Strategic initiatives
- 10.8.13. West Medica Produktions- und Handels- GmbH (West Medica)
  - 10.8.13.1. Overview
  - 10.8.13.2. Financial performance
  - 10.8.13.3. Product benchmarking
  - 10.8.13.4. Strategic initiatives
- 10.8.14. aetherAI
  - 10.8.14.1. Overview
  - 10.8.14.2. Financial performance
  - 10.8.14.3. Product benchmarking
  - 10.8.14.4. Strategic initiatives
- 10.8.15. IBEX (IBEX MEDICAL ANALYTICS)
  - 10.8.15.1. Overview
  - 10.8.15.2. Financial performance
  - 10.8.15.3. Product benchmarking
  - 10.8.15.4. Strategic initiatives
- 10.8.16. SigTuple Technologies Private Limited Morphle Labs, Inc
  - 10.8.16.1. Overview
  - 10.8.16.2. Financial performance
  - 10.8.16.3. Product benchmarking
  - 10.8.16.4. Strategic initiatives
- 10.8.17. Morphle Labs, Inc
  - 10.8.17.1. Overview
  - 10.8.17.2. Financial performance
  - 10.8.17.3. Product benchmarking
  - 10.8.17.4. Strategic initiatives
- 10.8.18. Bionovation Biotech, Inc.
  - 10.8.18.1. Overview
  - 10.8.18.2. Financial performance
  - 10.8.18.3. Product benchmarking
  - 10.8.18.4. Strategic initiatives
- 10.8.19. Scopio labs
  - 10.8.19.1. Overview
  - 10.8.19.2. Financial performance
  - 10.8.19.3. Product benchmarking
  - 10.8.19.4. Strategic initiatives
- 10.8.20. Inspirata, Inc
  - 10.8.20.1. Overview
  - 10.8.20.2. Financial performance
  - 10.8.20.3. Product benchmarking
  - 10.8.20.4. Strategic initiatives
- 10.8.21. Path Hub
  - 10.8.21.1. Overview
  - 10.8.21.2. Financial performance
  - 10.8.21.3. Product benchmarking
  - 10.8.21.4. Strategic initiatives
- 10.8.22. Sectra AB
  - 10.8.22.1. Overview
  - 10.8.22.2. Financial performance
  - 10.8.22.3. Product benchmarking
  - 10.8.22.4. Strategic initiatives
- 10.8.23. Agfa-Gevaert Group
  - 10.8.23.1. Overview
  - 10.8.23.2. Financial performance
  - 10.8.23.3. Product benchmarking
  - 10.8.23.4. Strategic initiatives
- 10.8.24. OptraScan
  - 10.8.24.1. Overview
  - 10.8.24.2. Financial performance
  - 10.8.24.3. Product benchmarking
  - 10.8.24.4. Strategic initiatives
- 10.8.25. Agilent Technologies, Inc.
  - 10.8.25.1. Overview
  - 10.8.25.2. Financial performance
  - 10.8.25.3. Product benchmarking
  - 10.8.25.4. Strategic initiatives
- 10.8.26. KFBIO
  - 10.8.26.1. Overview
  - 10.8.26.2. Financial performance
  - 10.8.26.3. Product benchmarking
  - 10.8.26.4. Strategic initiatives
10.9. Company Profiles of AI-enabled Digital Pathology Solution Providers
- 10.9.1. Aiosyn
  - 10.9.1.1. Overview
  - 10.9.1.2. Financial performance
  - 10.9.1.3. Product benchmarking
  - 10.9.1.4. Strategic initiatives
- 10.9.2. Proscia Inc.
  - 10.9.2.1. Overview
  - 10.9.2.2. Financial performance
  - 10.9.2.3. Product benchmarking
  - 10.9.2.4. Strategic initiatives
- 10.9.3. EVIDENT
  - 10.9.3.1. Overview
  - 10.9.3.2. Financial performance
  - 10.9.3.3. Product benchmarking
  - 10.9.3.4. Strategic initiatives
- 10.9.4. Aignostics, Inc.
  - 10.9.4.1. Overview
  - 10.9.4.2. Financial performance
  - 10.9.4.3. Product benchmarking
  - 10.9.4.4. Strategic initiatives
- 10.9.5. Aiforia/ Aiforia Technologies PLC
  - 10.9.5.1. Overview
  - 10.9.5.2. Financial performance
  - 10.9.5.3. Product benchmarking
  - 10.9.5.4. Strategic initiatives
- 10.9.6. Qritive
  - 10.9.6.1. Overview
  - 10.9.6.2. Financial performance
  - 10.9.6.3. Product benchmarking
  - 10.9.6.4. Strategic initiatives
- 10.9.7. Mindpeak GmbH
  - 10.9.7.1. Overview
  - 10.9.7.2. Financial performance
  - 10.9.7.3. Product benchmarking
  - 10.9.7.4. Strategic initiatives
- 10.9.8. Dedalus S.p.A
  - 10.9.8.1. Overview
  - 10.9.8.2. Financial performance
  - 10.9.8.3. Product benchmarking
  - 10.9.8.4. Strategic initiatives
- 10.9.9. Gestalt
  - 10.9.9.1. Overview
  - 10.9.9.2. Financial performance
  - 10.9.9.3. Product benchmarking
  - 10.9.9.4. Strategic initiatives
- 10.9.10 CGI Inc. Overview
  - 10.9.10.1. Financial performance
  - 10.9.10.2. Product benchmarking
  - 10.9.10.3. Strategic initiatives

한글목차

디지털 병리학 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 디지털 병리학 시장 : 추정 및 동향 분석

제4장 디지털 병리학 시장 : 제품별 추정 및 동향 분석

제5장 디지털 병리학 시장 : 유형별 추정 및 동향 분석

제6장 디지털 병리학 시장 : 용도별 추정 및 동향 분석

제7장 디지털 병리학 시장 : 치료 영역별 추정 및 동향 분석

제8장 디지털 병리학 시장 : 최종 용도별 추정 및 동향 분석